Esperion Therapeutics, Inc. (ESPR)
Largest Insider Buys in Sector
ESPR Stock Price History Chart
ESPR Stock Performance
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule …
Insider Activity of Esperion Therapeutics, Inc.
Over the last 12 months, insiders at Esperion Therapeutics, Inc. have bought $0 and sold $51,657 worth of Esperion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Esperion Therapeutics, Inc. have bought $4.34M and sold $98,014 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,091 shares for transaction amount of $36,285 was made by CARROLL J MARTIN (director) on 2023‑05‑11.
List of Insider Buy and Sell Transactions, Esperion Therapeutics, Inc.
| 2024-11-19 | Sale | Chief Commercial Officer | 197 <0.0001% | $2.17 | $427 | +11.55% | ||
| 2024-10-17 | Sale | Chief Commercial Officer | 107 <0.0001% | $2.12 | $227 | +0.95% | ||
| 2024-09-17 | Sale | President and CEO | 14,550 0.0075% | $1.80 | $26,132 | +16.01% | ||
| 2024-09-17 | Sale | Chief Commercial Officer | 2,608 0.0013% | $1.78 | $4,650 | +16.01% | ||
| 2024-08-19 | Sale | Chief Commercial Officer | 211 0.0001% | $1.95 | $411 | +0.53% | ||
| 2024-07-17 | Sale | Chief Medical Officer | 917 0.0005% | $2.60 | $2,383 | -23.47% | ||
| 2024-07-17 | Sale | Chief Commercial Officer | 108 <0.0001% | $2.59 | $279 | -23.47% | ||
| 2024-06-18 | Sale | Chief Medical Officer | 3,285 0.0019% | $2.87 | $9,418 | -25.37% | ||
| 2024-06-18 | Sale | Chief Commercial Officer | 2,540 0.0015% | $2.86 | $7,254 | -25.37% | ||
| 2024-05-17 | Sale | Chief Commercial Officer | 192 0.0001% | $2.48 | $477 | -10.64% | ||
| 2023-09-20 | Sale | Chief Commercial Officer | 742 0.0008% | $1.25 | $924 | +80.87% | ||
| 2023-08-18 | Sale | Chief Commercial Officer | 243 0.0003% | $1.41 | $344 | +43.79% | ||
| 2023-07-19 | Sale | Chief Commercial Officer | 106 0.0001% | $1.58 | $168 | +33.12% | ||
| 2023-06-21 | Sale | Chief Commercial Officer | 603 0.0008% | $1.48 | $894 | +33.80% | ||
| 2023-05-17 | Sale | Chief Commercial Officer | 219 0.0003% | $1.62 | $356 | -9.09% | ||
| 2023-05-11 | director | 23,091 0.031% | $1.57 | $36,285 | +6.71% | |||
| 2023-05-10 | director | 8,409 0.011% | $1.49 | $12,545 | +8.90% | |||
| 2023-05-10 | director | 8,111 0.0106% | $1.50 | $12,126 | +8.90% | |||
| 2023-05-09 | President and CEO | 20,000 0.0226% | $1.26 | $25,192 | +11.27% | |||
| 2023-04-19 | Sale | Chief Medical Officer | 938 0.0012% | $1.27 | $1,192 | +15.86% |
Insider Historical Profitability
| Koenig Sheldon L. | President and CEO | 752266 0.3818% | $2.52 | 2 | 6 | +3.99% |
| Warren Eric | Chief Commercial Officer | 162355 0.0824% | $2.52 | 1 | 21 | <0.0001% |
| BIOTECH TARGET N V | 10 percent owner | 4477964 2.2727% | $2.52 | 21 | 0 | <0.0001% |
| DOMAIN PARTERS VII L P | 10 percent owner | 2566935 1.3028% | $2.52 | 2 | 0 | +89.57% |
| Alta Partners VIII, L.P. | 10 percent owner | 2552189 1.2953% | $2.52 | 2 | 0 | +89.57% |
Institutional Investor Ownership
| OrbiMed | $36.74M | 7.24 | 13.71M | New | +$36.74M | 0.28 | |
| Bellevue Group | $26.65M | 5.25 | 9.94M | +136.52% | +$15.38M | 0.41 | |
| Wasatch Advisors | $24.47M | 4.82 | 9.13M | +2.68% | +$639,297.92 | 0.13 | |
| The Vanguard Group | $23.66M | 4.66 | 8.83M | +71.8% | +$9.89M | <0.0001 | |
| Great Point Partners | $21.44M | 4.22 | 8M | New | +$21.44M | 3.59 |